Semaglutide starts at ~$249/month on a standard plan, dropping to ~$199/month with a 3-month supply
This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or CKD [chronic kidney disease], said lead author Sunil Badve, professorial fellow at The George Institute for Global Health and UNSW Sydney
The Wolverine Stack, which combines BPC-157 with TB-500, is $795 per cycle
In this setting, studies that evaluate novel medications for T2DM are well-positioned to evaluate cardiovascular risk, resulting in a surge of data on managing patients with both T2DM and CVD
Pharmacists should be aware of berberines availability, recent popularity, associated claims, and evidence base to support informed discussions with patients and help determine whether it may be an appropriate option